Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2025-01-13 Board/Management Inform…
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
Board/Management Information Classification · 99% confidence The document is a press release dated January 13, 2025, announcing the appointment of Dr. Sonya Montgomery as Chief Development Officer. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information. Filing Category Check: - 10-K/IR: Not a full annual or interim financial report. - ER: Not an earnings release. - CT: Not a call transcript. - MANG (Board/Management Information): Matches perfectly as it announces a key executive appointment. - RPA/RNS: While it is a public announcement, MANG is more specific for management changes. Conclusion: The document is a management announcement regarding a new executive appointment.
2025-01-13 English
Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions composant le capital" (Information relating to the total number of voting rights and shares comprising the capital). It explicitly states the total number of shares and voting rights as of December 31, 2024, referencing French commercial code (Article L. 233-8 II du Code de commerce) and AMF regulations (Article 223-16 du Règlement général de l'AMF). This type of mandatory periodic disclosure regarding the total share capital and voting rights structure is typically classified under Share Issue/Capital Change (SHA) or sometimes as a general Regulatory Filing (RNS). Given the specific focus on the total number of shares and voting rights, SHA is the most precise fit, as it relates directly to the capital structure, even though it's a periodic update rather than a new issuance announcement. It is not an AGM-R, DVA (as it's not voting results), or a general earnings report.
2025-01-06 French
OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO
Regulatory Filings Classification · 99% confidence The document is a press release from OSE Immunotherapeutics dated December 18, 2024, announcing that clinical results for their drug Lusvertikimab will be presented at the 20th ECCO congress in February 2025. The text details the abstract acceptance, presentation time, and scientific context. This type of announcement, which informs the public about the upcoming presentation of scientific/clinical data at a conference, is best classified as an Investor Presentation (IP) if it were the presentation itself, or more accurately, a general announcement related to investor/scientific communication. Since it is a press release announcing the presentation of clinical data (which is often a precursor to or summary of an Investor Presentation or Earnings Release content), and it is not a formal regulatory filing like a 10-K or a transcript, it fits best under the category of Investor Presentation (IP) as it is directly aimed at communicating scientific progress to investors and the medical community. It is not a formal Earnings Release (ER) as it focuses on a specific clinical data presentation rather than period financial results, nor is it a Report Publication Announcement (RPA) because it is announcing a future presentation, not the publication of a formal company report like an Annual Report or Interim Report.
2024-12-18 French
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO
Regulatory Filings Classification · 99% confidence The document is a press release from OSE Immunotherapeutics announcing that clinical abstract results regarding their drug Lusvertikimab for Ulcerative Colitis have been accepted for Oral Presentation at the 20th Congress of ECCO. It details the presentation time, session name, and includes commentary from the CEO, background on the disease, and company information. This format—announcing upcoming presentation of scientific data—is characteristic of an Investor Presentation (IP) or a general announcement. Since it is a formal announcement detailing scientific findings and strategic updates intended for investors and the public, and it is not a full regulatory report (like 10-K or IR) nor a transcript of a call, the most fitting category is Investor Presentation (IP). It is not a Report Publication Announcement (RPA) because it is announcing the presentation of *abstract* results, not the publication of a full financial report itself.
2024-12-18 English
OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son vaccin thérapeutique contre le cancer en développement avancé
Earnings Release Classification · 95% confidence The document is a press release dated December 11, 2024, from OSE Immunotherapeutics SA, announcing positive clinical advancements for its drug Tedopi®. It details updates on four ongoing clinical trials (ARTEMIA, TEDOVA, CombiTED, TEDOPaM), including recruitment status and expected results dates. This format—a concise announcement highlighting key operational and clinical milestones, often issued outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general press release summarizing operational progress. Since it focuses on clinical trial progress and operational updates rather than comprehensive financial statements (like 10-K or IR) or a formal transcript (CT), it best fits the 'Earnings Release' category, which often includes operational highlights accompanying financial results, or a general regulatory announcement. Given the focus on 'avancées cliniques positives' and the structure of a news announcement, ER is the most appropriate fit among the provided options, as these updates frequently accompany earnings announcements. It is not a full financial report (10-K, IR) nor a proxy statement (DEF 14A). It is an announcement of operational progress, which aligns closely with the scope of an ER. Q4 2024
2024-12-11 French
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®
Earnings Release Classification · 95% confidence The document is a press release dated December 11, 2024, announcing positive clinical progress for the cancer vaccine Tedopi®. It details updates across several ongoing clinical trials (ARTEMIA, TEDOVA, CombiTED, TEDOPaM) and provides expected readout timelines. This format—a formal announcement of operational and clinical milestones, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on operational updates and clinical progress rather than summarizing comprehensive financial results (which would be an ER or IR), and it is not a short announcement linking to a separate report (which would be RPA), it fits best as a general announcement. Given the options, 'Earnings Release' (ER) is often used broadly for significant operational updates that impact investor outlook, but 'Regulatory Filings' (RNS) serves as the best general category for non-standard, material operational news releases that don't fit the specific financial report codes. However, press releases detailing clinical trial progress and operational milestones are frequently classified as Earnings Releases (ER) when they provide forward-looking guidance or significant updates that influence investor perception, even if they don't contain full financial statements. Since it provides specific timelines for results and operational status, ER is a strong candidate, but RNS is the safest fallback. Given the content is a major operational update, I will classify it as an Earnings Release (ER) as it serves the function of informing the market of key performance indicators (clinical progress). Q4 2024
2024-12-11 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.